Reuters logo
BRIEF-Intellia therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9
September 26, 2017 / 11:43 AM / in 2 months

BRIEF-Intellia therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9

Sept 26 (Reuters) - Intellia Therapeutics Inc

* Intellia Therapeutics demonstrates sustained and durable genome editing with CRISPR/Cas9 in one-year animal study

* Intellia Therapeutics Inc - ‍investigational new drug-enabling activities on track for initiation in first half 2018​

* Intellia Therapeutics Inc says genome editing treatment was well tolerated with no adverse events during course of 12-month study Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below